InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Pam3CSK4 | SARS-CoV-2 suppresses TLR4-induced immunity by dendritic cells via C-type lec... | 2023 | PLoS Pathog. | van der Donk L.E.H. et al. | DOI: 10.1371/journal.ppat.1011735 |
| FLA-BS (Standard or Ultrapure) | SARS-CoV-2 suppresses TLR4-induced immunity by dendritic cells via C-type lec... | 2023 | PLoS Pathog. | van der Donk L.E.H. et al. | DOI: 10.1371/journal.ppat.1011735 |
| Poly(I:C) HMW | SARS-CoV-2 suppresses TLR4-induced immunity by dendritic cells via C-type lec... | 2023 | PLoS Pathog. | van der Donk L.E.H. et al. | DOI: 10.1371/journal.ppat.1011735 |
| LTA-SA | SARS-CoV-2 suppresses TLR4-induced immunity by dendritic cells via C-type lec... | 2023 | PLoS Pathog. | van der Donk L.E.H. et al. | DOI: 10.1371/journal.ppat.1011735 |
| Poly(I:C) (HMW) VacciGrade™ | Calorie restriction partially attenuates sickness behavior induced by viral m... | 2023 | Behav Brain Res. | De Luca S.N. et al. | DOI: 10.1016/j.bbr.2023.114715 |
| Normocin® - Antimicrobial Reagent | DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune respo... | 2023 | Commun Biol. | Fan H. et al. | DOI: 10.1038/s42003-023-05412-x |
| Plasmocure™ - Mycoplasma Elimination Reagent | DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune respo... | 2023 | Commun Biol. | Fan H. et al. | DOI: 10.1038/s42003-023-05412-x |
| Puromycin | DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune respo... | 2023 | Commun Biol. | Fan H. et al. | DOI: 10.1038/s42003-023-05412-x |
| QUANTI-Luc™: Luciferase Detection Reagent | Activation of human STING by a molecular glue-like compound. | 2023 | Nat Chem Biol. | Li J. et al. | DOI: 10.1038/s41589-023-01434-y |
| THP1-Dual™ Cells | Activation of human STING by a molecular glue-like compound. | 2023 | Nat Chem Biol. | Li J. et al. | DOI: 10.1038/s41589-023-01434-y |
| ODN 1826 VacciGrade™ | Negligible role for pneumococcal surface protein A (PspA) and pneumococcal su... | 2023 | Microb Pathog. | Araujo A.P. et al. | DOI: 10.1016/j.micpath.2023.106391 |
| AddaS03™ Adjuvant | Negligible role for pneumococcal surface protein A (PspA) and pneumococcal su... | 2023 | Microb Pathog. | Araujo A.P. et al. | DOI: 10.1016/j.micpath.2023.106391 |
| TLR4-based adjuvant - MPLA-SM VacciGrade™ | Negligible role for pneumococcal surface protein A (PspA) and pneumococcal su... | 2023 | Microb Pathog. | Araujo A.P. et al. | DOI: 10.1016/j.micpath.2023.106391 |
| Primocin® | Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical i... | 2023 | iScience | Uraki R. et al. | DOI: 10.1016/j.isci.2023.108147 |
| G418 (Geneticin) | Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical i... | 2023 | iScience | Uraki R. et al. | DOI: 10.1016/j.isci.2023.108147 |
| Plasmocin® - Mycoplasma Elimination Reagent | Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical i... | 2023 | iScience | Uraki R. et al. | DOI: 10.1016/j.isci.2023.108147 |
| Ruxolitinib | Ruxolitinib accelerates Influenza A virus adaptation in the MDCK cell line. | 2023 | J Appl Microbiol. | Malenovská H. | DOI: 10.1093/jambio/lxad232 |
| LPS-EB (LPS from E. coli O111:B4) | PSGL-1 Blockade Induces Classical Activation of Human Tumor-Associated Macrop... | 2023 | Cancer Res Commun. | Kauffman K. et al. | DOI: 10.1158/2767-9764.CRC-22-0513 |
| Human TLR7 Reporter HEK293 Cells (NF-κB) | Influence of antigen density and TLR ligands on preclinical efficacy of a VLP... | 2023 | Allergy | Krenger P.S. et al. | DOI: 10.1111/all.15897 |
| Alhydrogel® adjuvant 2% | Influence of antigen density and TLR ligands on preclinical efficacy of a VLP... | 2023 | Allergy | Krenger P.S. et al. | DOI: 10.1111/all.15897 |